美国 · SEC FORM 4
AEON Biopharma, Inc.
AEON · NYSE · CIK 0001837607 · Healthcare · Biotechnology
内部人信号
1 位买方 · 1 条买入交易行 · $241.5K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ 角色得分低 · 买入者中职位最高的是：TenPercentOwner（CEO、董事长和持股 10% 以上的股东得分最低）
- ⚠ Purchase activity is becoming less recent
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
买方广度与集中度
Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
最新留档分数
- 46.2
- 46.1
- 46.0
- 45.8
- 45.8
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- +5.9%
- 3M
- -61.4%
- 6M
- -70.3%
- 12M
- -66.9%
波动率与流动性
- 波动率
- 149.7%
- Beta
- —
- 平均每日成交额
- —
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- —
- ROE
- —
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-05 · 价格来源：OpenBB/yfinance · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,171,628
- 上期报告
- 2,947,951
- 日均成交量
- 11,385,809
- 回补天数
- ≤ 1.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | LYNCH TIMOTHY P | 买入 (P) | Class A Common Stock | 1,150,000 | USD 0.21 | USD 241,500 | SEC 申报 ↗ |
| 2025-05-21 | FISCHER JOST | 买入 (P) | Class A Common Stock | 60,000 | USD 0.49 | USD 29,400 | SEC 申报 ↗ |
| 2025-05-20 | FISCHER JOST | 买入 (P) | Class A Common Stock | 60,000 | USD 0.51 | USD 30,600 | SEC 申报 ↗ |
| 2025-05-19 | FISCHER JOST | 买入 (P) | Class A Common Stock | 50,000 | USD 0.50 | USD 25,000 | SEC 申报 ↗ |
Form 4 申报证据
14 transaction lines in the latest 365-day window; 32 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | LYNCH TIMOTHY P | 买入 (P) | Class A Common Stock | 1,150,000 | USD 0.21 | USD 241,500 | SEC 申报 ↗ |
| 2026-06-17 | Thunen Shelley B | 奖励／授予 (A) | Class A Common Stock | 222,684 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | PALMISANO ROBERT J | 奖励／授予 (A) | Class A Common Stock | 222,684 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (14 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | LYNCH TIMOTHY P | 买入 (P) | Class A Common Stock | 1,150,000 | USD 0.21 | USD 241,500 | SEC 申报 ↗ |
| 2026-06-17 | Thunen Shelley B | 奖励／授予 (A) | Class A Common Stock | 222,684 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | PALMISANO ROBERT J | 奖励／授予 (A) | Class A Common Stock | 222,684 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Forth Marc | 奖励／授予 (A) | Class A Common Stock | 222,684 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | FISCHER JOST | 奖励／授予 (A) | Class A Common Stock | 222,684 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Carter Eric G | 奖励／授予 (A) | Class A Common Stock | 222,684 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-02 | Bencich John | 奖励／授予 (A) | Class A Common Stock | 754,717 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | Oh Chad | 奖励／授予 (A) | Class A Common Stock | 1,316,872 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | Wilson Alexander Blair | 奖励／授予 (A) | Class A Common Stock | 1,316,872 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | Sy Jennifer | 奖励／授予 (A) | Class A Common Stock | 925,925 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Oh Chad | 奖励／授予 (A) | Class A Common Stock | 862,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Wilson Alexander Blair | 奖励／授予 (A) | Class A Common Stock | 862,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Sy Jennifer | 奖励／授予 (A) | Class A Common Stock | 575,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-17 | Bancroft Robert E. | 奖励／授予 (A) | Class A Common Stock | 3,000,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | AEON |
| CIK | 0001837607 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | NYSE |
数据覆盖
| 本地 Form 4 历史 | 32 transaction lines from 2023-07-21 to 2026-08-19 4 P purchase lines · 1 S sale lines · 27 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.